与左乙拉西坦相关的B细胞发育不全和低丙种球蛋白血症。
B cell aplasia and hypogammaglobulinemia associated with levetiracetam.
作者信息
Ozdemir Hulya, Sumer Sua, Karabagli Hakan, Akdemir Gokhan, Caliskaner A Zafer, Artac Hasibe
机构信息
Hulya Ozdemir, Department of Pediatric Immunology and Allergy,, Medical Faculty, Selcuk University,, Alaeddin Keykubat Campus,, 42130 Selcuklu/Konya, Turkey, T: +90 332 2244496,
出版信息
Ann Saudi Med. 2018 Jan-Feb;38(1):65-68. doi: 10.5144/0256-4947.2018.09.01.1430. Epub 2018 Jan 9.
UNLABELLED
Levetiracetam (LEV) is a second-generation antiepileptic drug approved for the treatment of several types of epilepsy. We report a 45-year-old female who developed hypogammaglobulinemia and B cell aplasia during LEV treatment. The Naranjo probability score for an adverse drug reaction was 6. After LEV discontinuation, the number of B cells gradually increased and reached normal levels within two months. This case suggests that monitoring of immunoglobulin levels and lymphocyte subsets analysis is important in patients treated with LEV, especially in cases of prolonged infections.
SIMILAR CASES PUBLISHED
未标注
左乙拉西坦（LEV）是一种被批准用于治疗多种类型癫痫的第二代抗癫痫药物。我们报告了一名45岁女性，她在接受左乙拉西坦治疗期间出现了低丙种球蛋白血症和B细胞发育不全。药物不良反应的纳兰霍概率评分是6分。停用左乙拉西坦后，B细胞数量逐渐增加，并在两个月内恢复到正常水平。该病例表明，在接受左乙拉西坦治疗的患者中，监测免疫球蛋白水平和淋巴细胞亚群分析很重要，尤其是在长期感染的情况下。
已发表的类似病例
1例。
Zotero 插件